Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

562
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
562
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

634
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
634
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Cross-bridge Cycle01:26

Cross-bridge Cycle

117.8K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.8K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.1K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathology and Genetics in a Global Cohort of Parkinsonian Disorders.

JAMA neurology·2026
Same author

Novel Variants in PUS7 Associated With Intellectual Disability and Growth Retardation: Expanding the Clinical Spectrum in 13 Patients.

Clinical genetics·2026
Same author

COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy.

Nature communications·2026
Same author

Clinical prognostic indicators in multiple system atrophy.

Brain : a journal of neurology·2026
Same author

Variants in the proteasome regulator PSMF1 cause a phenotypic spectrum from parkinsonism to perinatal lethality.

Nature communications·2026
Same author

DRD1-driven infantile dystonia: towards a mechanism-informed framework for GPCR receptoropathies.

Brain : a journal of neurology·2026
Same journal

Neurological signs of possible diagnostic value in the cognitive clinic: past, present and future.

Practical neurology·2026
Same journal

Longitudinally extensive myelitis in neurosarcoidosis.

Practical neurology·2026
Same journal

Patient with bilateral horizontal gaze palsy.

Practical neurology·2026
Same journal

Orofacial pain beyond trigeminal neuralgia.

Practical neurology·2026
Same journal

Are all antibody panels equal?

Practical neurology·2026
Same journal

Management of subdural haematoma: a practical guide.

Practical neurology·2026
See all related articles

Related Experiment Video

Updated: Aug 6, 2025

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

32.0K

Multiple system atrophy.

Yee Yen Goh1, Emma Saunders2, Samantha Pavey2

  • 1Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.

Practical Neurology
|March 17, 2023
PubMed
Summary
This summary is machine-generated.

This guide aids in diagnosing and managing multiple system atrophy (MSA). It details new criteria to shorten diagnosis time and offers practical symptom management strategies to improve quality of life for those with MSA.

Keywords:
CEREBELLAR DEGENERATIONCLINICAL NEUROLOGYMOVEMENT DISORDERSMULTISYSTEM ATROPHY

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.4K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

Related Experiment Videos

Last Updated: Aug 6, 2025

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

32.0K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.4K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

Area of Science:

  • Neurology
  • Movement Disorders

Background:

  • Multiple system atrophy (MSA) is a rare neurodegenerative disorder.
  • Timely diagnosis and effective management are crucial for patient outcomes.

Purpose of the Study:

  • To provide a practical guide for diagnosing and managing multiple system atrophy (MSA).
  • To explain the latest Movement Disorders Society Consensus Diagnostic Criteria for MSA.
  • To offer strategies for symptom management to enhance the quality of life for individuals with MSA.

Main Methods:

  • Explanation of the new Movement Disorders Society Consensus Diagnostic Criteria for MSA.
  • Highlighting key clinical features for MSA diagnosis.
  • Listing common MSA mimics and differentiation methods.
  • Discussing practical approaches to symptom management in MSA.

Main Results:

  • Introduction of 'Clinically Established MSA' and 'Possible Prodromal MSA' categories.
  • Emphasis on key clinical features to facilitate accurate diagnosis.
  • Provision of methods to differentiate MSA from similar conditions.
  • Strategies for managing MSA symptoms and side effects.

Conclusions:

  • The updated diagnostic criteria aim to reduce the time to diagnosis for MSA.
  • Comprehensive clinical features and differentiation methods support accurate identification.
  • Practical symptom management strategies are essential for improving the quality of life in MSA patients.